FDA Again Blasts Pfizer Unit Over Quality-Control Mishaps

Law360, New York (December 2, 2013, 7:50 PM EST) -- Pfizer Inc. unit Meridian Medical Technologies Inc. botched several aspects of quality control surrounding production of nerve agent antidotes that have subsequently fallen into short supply, according to a U.S. Food and Drug Administration inspection report released Friday that echoed previous criticism. 

In its report, the FDA described numerous problems allegedly uncovered during visits in March and April to a Meridian plant in the St. Louis area, including failing to identify the root cause of manufacturing problems that left injections of pralidoxime and atropine without the...
To view the full article, register now.